
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Combined technologies from Agilent Technologies and Picometrics Technologies are designed for large–molecule analysis.
A number of Agilent products can be combined with Picometrics ZETALIF LED and ZETALIF LASER instruments, including Agilent’s Capillary Electrophoresis and CE/MS technologies, as well as HPLC/UHPLC solutions.
The platform is suited for the research and development of complex large-molecule biopharmaceutical compounds, the companies report.
Source:






